Replies to post #743585 on NorthWest Biotherapeutics Inc (NWBO)

[tunnelvisionofplenty]

Wow, nice find! Will be interesting to see if that prediction pans out; they did prove over-optimistic in the August release which you flagged. If and when they are approved, that's just one less candidate in the pipeline ahead of DCVax-L.

[flipper44]

I actually think NWBO received their “assessment report” before Telix — perhaps by two or three weeks. I base that upon their August 2, 2024 8K.

Anyway, it’s just my opinion, but I think Telix and NWBO are looking at this month of January very attentively.

See recent posts by Lykiri and tunnelvisionaplenty

[FeMike]

It's wild and unfair that NWBO has to play by different rules than other companies. Or maybe Linda Powerless is just a liar and/or moron.

NWBO: " We will not update anyone on anything throughout the entire process. It's simply not allowed. That is how all other companies do it, so that is how we will do it"

Other Companies: "Here's every possibly fucking update we can give shareholders on the status with every RA every step of the way, and our guess as to when things will happen, yay stock price!"

Illuccix® global regulatory submissions: The German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, or BfArM) is expected to provide its decision on the Company’s EU marketing authorization application on 15 January 2025. In the United Kingdom (UK), the Company has responded to all queries with no substantive issues raised. The UK regulator (the Medicines and Healthcare products Regulatory Agency - MHRA) is experiencing significant administrative delays but an approval decision is expected this month. The Brazilian Health Regulatory Agency (ANVISA) is expected to provide a decision imminently after protracted administrative delays also unrelated to Telix’s marketing authorization application.

Telix is expecting to receive a regulator’s assessment report by the end of July 2024 from the UK Medicines & Healthcare Products Regulatory Agency (MHRA)

The UK Medicines & Healthcare Products Regulatory Agency
(MHRA) regulator's assessment report has been received with no substantive issues raised. Decisions expected in H2 2024

The Company's MAA to MHRA in the U.K. is in the active process of responses to questions received from MHRA. Nymox will update later in the cycle when appropriate

So, either these companies will all have their applications rejected for breaking the rules and updating their shareholders on progress. Or Linda Powerless is a lying sack of shit.